Journal article icon

Journal article

Neurocognitive function at the first-line failure and on the second-line antiretroviral therapy in Africa: Analyses from the EARNEST trial.

Abstract:

OBJECTIVE: To assess neurocognitive function at the first-line antiretroviral therapy failure and change on the second-line therapy. DESIGN: Randomized controlled trial was conducted in 5 sub-Saharan African countries. METHODS: Patients failing the first-line therapy according to WHO criteria after >12 months on non-nucleoside reverse transcriptase inhibitors-based regimens were randomized to the second-line therapy (open-label) with lopinavir/ritonavir (400 mg/100 mg twice daily) plus eit...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1097/QAI.0000000000000898

Authors


Kambugu, A More by this author
Thompson, J More by this author
Walker, SA More by this author
Publisher:
Lippincott, Williams and Wilkins Publisher's website
Journal:
Journal of Acquired Immune Deficiency Syndrome Journal website
Volume:
71
Issue:
5
Pages:
506-513
Publication date:
2016-04-15
DOI:
EISSN:
1944-7884
ISSN:
1525-4135
Pubs id:
pubs:667924
URN:
uri:eeda60c1-55c3-4770-9e65-d14a000b9e8d
UUID:
uuid:eeda60c1-55c3-4770-9e65-d14a000b9e8d
Local pid:
pubs:667924
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP